Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
February 26, 2015 07:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
February 19, 2015 08:00 ET
|
Merrimack Pharmaceuticals
Trial is recruiting biomarker-selected patients previously treated with two lines of therapy for locally advanced or metastatic disease
Merrimack's first study to prospectively select patients...
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
February 12, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2014 Investor Conference Call and...
Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
January 22, 2015 17:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division....
Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
January 20, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study...
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
January 08, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that additional analyses from the Phase 3 NAPOLI-1 study of MM-398 (nanoliposomal...
Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 07, 2015 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 33rd Annual...
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
December 17, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Russell T. Ray to its Board of Directors, effective January 1,...
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
December 12, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in...
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
December 04, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that Cancer Research has published the paper "Preclinical Activity of Nanoliposomal...